Abstract | PURPOSE: METHODS: A prospective, double-masked, placebo-controlled, randomized clinical trial included 39 eyes with minimally classic or occult CNV secondary to AMD. The treatment group (21 eyes) received intravitreal injection (20-25 mg) of triamcinolone acetonide and the control group (18 eyes) received intravitreal injection (500 mug) of dexamethasone at 6-month intervals. Best-corrected ETDRS (Early Treatment Diabetic Retinopathy Study) score, contrast sensitivity score, and central macular volume were measured at 1 month, 3 months, 6 months, and 12 months. RESULTS: Mean baseline best-corrected visual acuity (BCVA [logarithm of the minimal angle of resolution]) was 0.64 (Snellen equivalent, 20/80) in each group. At 1 month, 3 months, and 6 months after the injection, neither group had a significant change in BCVA. At 12 months, mean BCVA +/- SD significantly decreased to 1.06 +/- 0.34 (Snellen equivalent, 20/200) in the treatment group (paired t-test, P < 0.001), whereas it was 0.78 +/- 0.52 (Snellen equivalent, 20/125) in the control group (P = 0.23). The difference was marginally significant (P = 0.06, Student's t-test). All phakic eyes in the treatment group developed marked cataract progression. CONCLUSIONS:
|
Authors | Jonghyun Lee, William R Freeman, Stanley P Azen, Eun Jee Chung, Hyoung Jun Koh |
Journal | Retina (Philadelphia, Pa.)
(Retina)
2007 Nov-Dec
Vol. 27
Issue 9
Pg. 1205-13
ISSN: 0275-004X [Print] United States |
PMID | 18046226
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Glucocorticoids
- Dexamethasone
- Triamcinolone Acetonide
|
Topics |
- Aged
- Choroidal Neovascularization
(drug therapy, etiology)
- Contrast Sensitivity
- Dexamethasone
(administration & dosage, adverse effects)
- Double-Blind Method
- Female
- Glucocorticoids
(administration & dosage, adverse effects)
- Humans
- Injections
- Intraocular Pressure
- Macular Degeneration
(complications, drug therapy)
- Male
- Middle Aged
- Prospective Studies
- Treatment Outcome
- Triamcinolone Acetonide
(administration & dosage, adverse effects)
- Visual Acuity
- Vitreous Body
|